AroCell AB (publ)
STO:AROC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (72.7), the stock would be worth kr-2.4 (544% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -16.4 | kr0.54 |
0%
|
| Industry Average | 72.7 | kr-2.4 |
-544%
|
| Country Average | 21.3 | kr-0.7 |
-230%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
A
|
AroCell AB (publ)
STO:AROC
|
124.4m SEK | -16.4 | -10.2 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 2 167.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 12.2 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 19.4 | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 190.3 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 21.5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | -40.7 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 36.5 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 107 | 46.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 9.8 | 19.7 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 31.6 | 29.7 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 12.2 |
| Median | 21.3 |
| 70th Percentile | 31.9 |
| Max | 19 008.8 |
Other Multiples
AroCell AB (publ)
Glance View
AroCell AB is a in vitro diagnostics company, which engages in the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2011-05-25. The firm's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
